<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041263</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Determinants of late-onset heart failure in myocardial infarction survivors: GISSI prevenzione trial results</dc:title>
<dc:description xml:lang="en">Introduction and objectives. Improvement in the early phase of myocardial infarction (MI) is associated with a higher rate of late complications, including late-onset heart failure (LHF). The factors predicting LHF are not well understood. Our aims were to identify the factors predicting LHF and to determine the survival rate in these patients. Patients and method. The GISSI-Prevenzione trial involved 11 323 low-risk patients (NYHA class &amp;#8804; II) who had had a recent MI (&lt; 3 months). It was a multicenter, open-label, clinical trial of the efficacy of treatment with polyunsaturated fatty acids, vitamin E, both, or neither. Patients with heart failure at baseline and those whose ejection fraction was unknown (n = 2908) were excluded from the present analysis. Late-onset heart failure was defined prospectively as hospital admission due to heart failure. A Cox regression model adjusted for major covariates was used for risk analysis. Results. The study included 8415 patients. During 3.5 years of follow-up, 192 (2.3%) developed LHF. The risk of LHF could be predicted from readily available parameters: age (per year; RR=1.07; 95% CI, 1.05-1.09), ejection fraction (per 1% increment; RR=0.96; 95% CI, 0.94-0.97), heart rate (&amp;#8805;74 beats/min; RR=1.62; 95% CI, 1.21-2.16), white blood cell count (&amp;#8805;8900 per ml; RR=1.42; 95% CI, 1.05-1.94), diabetes (RR=1.62; 95% CI, 1.17-2.24), hypertension (RR=1.76; 95% CI, 1.33-2.34), peripheral artery disease (RR=2.11; 95% CI, 1.32-3.37), and reinfarction (RR=2.09; 95% CI, 1.28-3.39). LHF was associated with poor survival: (RR=2.34; 95% CI, 1.63-3.36). Conclusions. The risk of LHF in post-MI patients can be predicted from readily available parameters. LHF was associated with a poor prognosisIntroduction and objectives. Improvement in the early phase of myocardial infarction (MI) is associated with a higher rate of late complications, including late-onset heart failure (LHF). The factors predicting LHF are not well understood. Our aims were to identify the factors predicting LHF and to determine the survival rate in these patients.                 Patients and method. The GISSI-Prevenzione trial involved 11 323 low-risk patients (NYHA class &amp;#8804; II) who had had a recent MI (&lt; 3 months). It was a multicenter, open-label, clinical trial of the efficacy of treatment with polyunsaturated fatty acids, vitamin E, both, or neither. Patients with heart failure at baseline and those whose ejection fraction was unknown (n = 2908) were excluded from the present analysis. Late-onset heart failure was defined prospectively as hospital admission due to heart failure. A Cox regression model adjusted for major covariates was used for risk analysis.                 Results. The study included 8415 patients. During 3.5 years of follow-up, 192 (2.3%) developed LHF. The risk of LHF could be predicted from readily available parameters: age (per year; RR=1.07; 95% CI, 1.05-1.09), ejection fraction (per 1% increment; RR=0.96; 95% CI, 0.94-0.97), heart rate (&amp;#8805;74 beats/min; RR=1.62; 95% CI, 1.21-2.16), white blood cell count (&amp;#8805;8900 per ml; RR=1.42; 95% CI, 1.05-1.94), diabetes (RR=1.62; 95% CI, 1.17-2.24), hypertension (RR=1.76; 95% CI, 1.33-2.34), peripheral artery disease (RR=2.11; 95% CI, 1.32-3.37), and reinfarction (RR=2.09; 95% CI, 1.28-3.39). LHF was associated with poor survival: (RR=2.34; 95% CI, 1.63-3.36).                 Conclusions. The risk of LHF in post-MI patients can be predicted from readily available parameters. LHF was associated with a poor prognosis</dc:description>
<dc:creator>Macchia, Alejandro</dc:creator>
<dc:creator>Marfisi, Rosa M</dc:creator>
<dc:creator>Franzosi, Maria G</dc:creator>
<dc:creator>Nicolosi, Gian L</dc:creator>
<dc:creator>Schweiger, Carlo</dc:creator>
<dc:creator>Maggioni, Aldo P</dc:creator>
<dc:creator>Tavazzi, Luigi</dc:creator>
<dc:creator>Levantesi, Giacomo</dc:creator>
<dc:creator>Tognoni, Gianni</dc:creator>
<dc:creator>Valagussa, Franco</dc:creator>
<dc:creator>Marchioli, Roberto</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos. La mejoría pronóstica de la etapa inicial del infarto conlleva un mayor número de complicaciones a largo plazo. Entre éstas destaca la insuficiencia cardíaca tardía (ICT). Los factores relacionados con la ICT no son del todo conocidos. El objetivo es determinar qué factores pronósticos se relacionan con la ICT y cuál es la supervivencia de estos pacientes. Pacientes y método. El estudio GISSI Prevenzione fue multicéntrico, abierto, aleatorizado y se estudió a 11.323 pacientes postinfarto reciente (&lt; 3 meses) de bajo riesgo (NYHA &amp;#8804; II) para evaluar la eficacia del tratamiento con ácidos grasos poliinsaturados, vitamina E, ambos o ninguno. Para este análisis se excluyó a los pacientes con insuficiencia cardíaca durante el ingreso y a aquellos sin determinación de la fracción de eyección (FE) (n = 2.908). La ICT se definió previamente como la necesidad de hospitalización por insuficiencia cardíaca. La predicción de riesgo se realizó con el modelo de Cox ajustado por diversas covariables. Resultados. Se incluyó a 8.415 pacientes. Durante 3,5 años de seguimiento, 192 pacientes (2,3%) desarrollaron ICT. Variables fácilmente asequibles permiten predecir el riesgo de ICT: edad (por año), riesgo relativo [RR] = 1,07; intervalo de confianza [IC] del 95%, 1,05-1,09), FE (por cada 1% de incremento, RR = 0,96; IC del 95%, 0,94-0,97), frecuencia cardíaca &amp;#8805; 74 lat/min (RR = 1,62; IC del 95%, 1,21-2,16), recuento de leucocitos &amp;#8805; 8.900/ml (RR = 1,42; IC del 95%, 1,05-1,94), diabetes (RR = 1,62; IC del 95%, 1,17-2,24), hipertensión (RR = 1,76; IC del 95%, 1,33-2,34), vasculopatía periférica (RR = 2,11; IC del 95%, 1,32-3,37) e infarto recurrente (RR = 2,09; IC del 95; 1,28-3,39). La ICT presentó mayor mortalidad alejada (RR = 2,34; IC del 95%, 1,63-3,36). Conclusiones. Elementos fácilmente asequibles en la consulta permiten predecir el riesgo de ICT en pacientes postinfarto. La ICT se asocia con un mal pronóstico</dc:description>
<dc:source>Rev Esp Cardiol;58(11): 1266-1272, nov. 2005. tab, graf</dc:source>
<dc:identifier>ibc-041263</dc:identifier>
<dc:title xml:lang="es">Determinantes de insuficiencia cardíaca tardía postinfarto de miocardio: resultados del estudio GISSI Prevenzione</dc:title>
<dc:subject>^d2834^s22062</dc:subject>
<dc:subject>^d6486^s22080</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d33939^s22045</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d9395^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5334^s22073</dc:subject>
<dc:subject>^d15211^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200511</dc:date>
</metadata>
</record>
</ibecs-document>
